Laura van Dussen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5525172/publications.pdf

Version: 2024-02-01

14	700	759233 12	1058476 14
papers	citations	h-index	g-index

14	14	14	899
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood, 2011, 118, e118-e127.	1.4	224
2	Malignancies and monoclonal gammopathy in <scp>G</scp>aucher disease; a systematic review of the literature. British Journal of Haematology, 2013, 161, 832-842.	2.5	98
3	Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells, Molecules, and Diseases, 2010, 44, 41-47.	1.4	88
4	Short-Term Effect of Estrogen on Human Bone Marrow Fat. Journal of Bone and Mineral Research, 2015, 30, 2058-2066.	2.8	61
5	Liver Fibrosis in Type I Gaucher Disease: Magnetic Resonance Imaging, Transient Elastography and Parameters of Iron Storage. PLoS ONE, 2013, 8, e57507.	2.5	45
6	Hepatocellular carcinoma in Gaucher disease: an international case series. Journal of Inherited Metabolic Disease, 2018, 41, 819-827.	3.6	37
7	Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4â€“5Âyears. British Journal of Haematology, 2012, 158, 528-538.	2.5	33
8	Gaucher disease: a model disorder for biomarker discovery. Expert Review of Proteomics, 2009, 6, 411-419.	3.0	31
9	Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose â€“ response relationships. Expert Opinion on Pharmacotherapy, 2009, 10, 2641-2652.	1.8	22
10	Lung Transplantation in Gaucher Disease. Chest, 2016, 149, e1-e5.	0.8	16
11	Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes. Haematologica, 2012, 97, 1850-1854.	3.5	15
12	Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study. Blood Cells, Molecules, and Diseases, 2010, 44, 181-187.	1.4	14
13	Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease. International Journal of Molecular Sciences, 2020, 21, 5784.	4.1	9
14	Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa. Journal of Inherited Metabolic Disease, 2018, 41, 1259-1265.	3.6	7